Literature DB >> 14658062

Homocysteine and left ventricular hypertrophy in children with chronic renal failure.

Hakan M Poyrazoğlu1, Ruhan Düşünsel, Figen Narin, Zübeyde Gündüz, Nazmi Narin, Musa Karakükçü, Fulya Tahan.   

Abstract

Hyperhomocysteinemia is recognized as an independent risk factor for cardiovascular disease, especially atherosclerosis, in adult patients with chronic renal failure (CRF). However, there is little information about the relationship between plasma homocysteine levels and left ventricular hypertrophy. The aim of this study was to determine plasma homocysteine levels and risk factors for left ventricular hypertrophy and to investigate the relationship between plasma homocysteine concentration and left ventricular mass index (LVMI) in children with CRF. The homocysteine level was measured by high-performance liquid chromatography and LVMI was calculated using echocardiographic findings in 27 children with CRF and 16 healthy controls. The mean LVMI and mean plasma homocysteine concentration in the CRF group, especially in patients with end-stage renal disease, were statistically higher than the control group ( P<0.05). There was no correlation between LVMI and plasma homocysteine concentration. There was a positive correlation between plasma homocysteine concentration and serum creatinine level. There was a positive correlation of LVMI with creatinine and blood pressures (systolic, diastolic, and mean arterial pressure). There was a negative correlation of LVMI with hemoglobin level in multiple linear regression analysis. In our view homocysteine does not have a direct effect on left ventricular structure and left ventricular hypertrophy is the end organ damage associated with hypertension, anemia, and CRF. More prospective studies are needed to better clarify the inter-relationships of plasma homocysteine level and left ventricular structure in children with CRF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14658062     DOI: 10.1007/s00467-003-1351-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

Review 1.  Hyperhomocysteinemia in chronic renal disease.

Authors:  A G Bostom; B F Culleton
Journal:  J Am Soc Nephrol       Date:  1999-04       Impact factor: 10.121

2.  Cardiovascular disease in chronic renal disease.

Authors:  A S Levey; G Eknoyan
Journal:  Nephrol Dial Transplant       Date:  1999-04       Impact factor: 5.992

Review 3.  Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes.

Authors:  A G Bostom; L Lathrop
Journal:  Kidney Int       Date:  1997-07       Impact factor: 10.612

4.  Left ventricular abnormalities in children, adolescents and young adults with renal disease.

Authors:  L M Johnstone; C L Jones; L E Grigg; J L Wilkinson; R G Walker; H R Powell
Journal:  Kidney Int       Date:  1996-09       Impact factor: 10.612

5.  High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients.

Authors:  A G Bostom; D Shemin; K L Lapane; A L Hume; D Yoburn; M R Nadeau; A Bendich; J Selhub; I H Rosenberg
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

6.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Authors:  R B Devereux; D R Alonso; E M Lutas; G J Gottlieb; E Campo; I Sachs; N Reichek
Journal:  Am J Cardiol       Date:  1986-02-15       Impact factor: 2.778

7.  Renal transplantation and cardiac function in pediatric patients.

Authors:  S O'Regan; M Y Douste-Blazy; G Ducharme; J C Fouron; A Davignon
Journal:  Clin Nephrol       Date:  1982-05       Impact factor: 0.975

8.  Hyperhomocyst(e)inaemia in children with chronic renal failure.

Authors:  M Lilien; M Duran; K Van Hoeck; B T Poll-The; C Schröder
Journal:  Nephrol Dial Transplant       Date:  1999-02       Impact factor: 5.992

9.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.

Authors:  A S Levey; J A Beto; B E Coronado; G Eknoyan; R N Foley; B L Kasiske; M J Klag; L U Mailloux; C L Manske; K B Meyer; P S Parfrey; M A Pfeffer; N K Wenger; P W Wilson; J T Wright
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

Review 10.  Lipoproteins and atherosclerosis in children: an early marriage?

Authors:  J P Strong; A W Zieske; G T Malcom
Journal:  Nutr Metab Cardiovasc Dis       Date:  2001-10       Impact factor: 4.222

View more
  5 in total

1.  Carotid artery thickness in children and young adults with end stage renal disease.

Authors:  Hakan M Poyrazoğlu; Ruhan Düşünsel; Ali Yikilmaz; Nazmi Narin; Ruksan Anarat; Zübeyde Gündüz; Abdulhakim Coşkun; Ali Baykan; Ahmet Oztürk
Journal:  Pediatr Nephrol       Date:  2006-08-30       Impact factor: 3.714

2.  Report of an NIH task force on research priorities in chronic kidney disease in children.

Authors:  Russell W Chesney; Eileen Brewer; Marva Moxey-Mims; Sandra Watkins; Susan L Furth; William E Harmon; Richard N Fine; Ronald J Portman; Bradley A Warady; Isidro B Salusky; Craig B Langman; Debbie Gipson; Peter Scheidt; Harold Feldman; Frederick J Kaskel; Norman J Siegel
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

Review 3.  Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management.

Authors:  Amy C Wilson; Mark M Mitsnefes
Journal:  Am J Kidney Dis       Date:  2009-08       Impact factor: 8.860

4.  Traditional and "new" cardiovascular risk markers and factors in pediatric dialysis patients.

Authors:  Mahmut Civilibal; Salim Caliskan; Huseyin Oflaz; Lale Sever; Cengiz Candan; Nur Canpolat; Ozgur Kasapcopur; Zehra Bugra; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2007-03-06       Impact factor: 3.714

5.  Differential expression of Gs in a murine model of homocysteinemic heart failure.

Authors:  Thomas P Vacek; Utpal Sen; Neetu Tyagi; Jonathan C Vacek; Munish Kumar; William M Hughes; John C Passmore; Suresh C Tyagi
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.